SLC5A2 and type 2 diabetes mellitus: Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) is a novel oral hypoglycemic agent for the treatment of T2DM, which reduces glucose reabsorption by inhibiting SGLT2 in the renal proximal tubules [6].